Forlong Biotechnology, a clinical-stage biotech company, announced a poster presentation for the 2026 American Society of Clinical Oncology Annual Meeting. The presentation will cover the safety, pharmacokinetics, and antitumor activities of its candidate, FL115, from a recent first-in-human study involving 11 patients. Initial dosing began in December 2023, with one patient remaining progression-free upon the study’s completion. FL115, an engineered IL-15 superagonist, aims to enhance anti-tumor immunity and is currently being tested in combination therapies for nonmuscle invasive bladder cancer and advanced solid tumors.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/forlong-biotechnology-to-present-clinical-data-from-the-first-in-human-study-for-fl115-il-15-superagonist-in-us-patients-with-advanced-solid-tumors-at-2026-asco-annual-meeting
